Sanofi (NASDAQ:SNY) Stake Raised by Prospera Financial Services Inc

Prospera Financial Services Inc increased its holdings in Sanofi (NASDAQ:SNYFree Report) by 5.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,432 shares of the company’s stock after buying an additional 604 shares during the quarter. Prospera Financial Services Inc’s holdings in Sanofi were worth $659,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. POM Investment Strategies LLC bought a new position in shares of Sanofi in the second quarter worth $25,000. Northwest Investment Counselors LLC bought a new position in Sanofi in the 3rd quarter valued at about $29,000. Concord Wealth Partners increased its stake in Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after buying an additional 363 shares during the period. Arrow Financial Corp bought a new stake in shares of Sanofi during the 2nd quarter worth about $35,000. Finally, Fortitude Family Office LLC boosted its holdings in shares of Sanofi by 708.6% in the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after acquiring an additional 659 shares in the last quarter. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

SNY has been the topic of several recent analyst reports. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th. Citigroup upgraded Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Sanofi presently has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Get Our Latest Stock Analysis on Sanofi

Sanofi Trading Up 0.6 %

Sanofi stock opened at $48.28 on Friday. The firm has a market cap of $122.53 billion, a price-to-earnings ratio of 24.63, a price-to-earnings-growth ratio of 1.22 and a beta of 0.61. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The firm’s 50 day moving average price is $53.70 and its two-hundred day moving average price is $52.17. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.

Sanofi (NASDAQ:SNYGet Free Report) last announced its earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. During the same period in the previous year, the firm earned $2.55 earnings per share. Sanofi’s revenue for the quarter was up 12.3% compared to the same quarter last year. On average, research analysts predict that Sanofi will post 4.29 EPS for the current fiscal year.

Sanofi Company Profile

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Featured Stories

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNYFree Report).

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.